Oryzon Genomics S.A.

ORY

ES0167733015

Biotechnology & Medical Research

Market Closed - BME Other stock markets 11:35:26 2024-04-26 am EDT			5-day change	1st Jan Change
2 ^EUR	+0.91%		+5.60%	+5.93%

Apr. 22	Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat	CI
Apr. 08	ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer	CI

Oryzon Genomics S.A. announced that it has received €1.800407 million in funding

December 19, 2022

Oryzon Genomics S.A. announced a private placement of 818,367 shares at an issue price of €2.2 per share for a gross proceeds of €800,407 on December 20, 2022.

Latest news about Oryzon Genomics S.A.

Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat	Apr. 22	CI
ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer	Apr. 08	CI
Oryzon Genomics S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 26	CI
Oryzon Genomics, S.A. Announces Topline Results from Phase IIb Portico Study of Vafidemstat in Borderline Personality Disorder	Jan. 05	CI
Oryzon Genomics S.A. announced that it expects to receive ?45 million in funding from Nice & Green SA	Nov. 20	CI
Oryzon Completes Patient Testing in Mid-stage Study of Borderline Personality Disorder Drug	Nov. 07	MT
Oryzon Genomics, S.A. Announces Last Patient Last Visit in Its Phase IIb Portico Study for Borderline Personality Disorder	Nov. 07	CI
Oryzon Genomics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-27	CI
Oryzon Genomics, S.A. Presents Blinded Aggregated Safety Data from Vafidemstat's Ongoing Phase IIB Portico Trial in Borderline Personal Disorder	23-10-10	CI
Oryzon Genomics S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-24	CI
Oryzon Genomics, S.A. Reports New Preliminary Blinded Aggregate Safety Data from Its Ongoing Phase IIb Portico Trial	23-07-05	CI
Oryzon Genomics, S.A. Presents Positive Preclinical Data of Ory-4001 for the Treatment of Charcot-Marie-Tooth Disease Presented At the 2023 Peripheral Nerve Society Annual Meeting	23-06-21	CI
Oryzon Genomics, S.A. to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth Disease At the 2023 Peripheral Nerve Society Annual Meeting	23-05-30	CI
Oryzon Genomics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Oryzon Genomics, S.A. Announces Positive Results from Planned Interim Analysis of PORTICO, a Phase 2b Adaptive Trial in Borderline Personality Disorder	23-04-03	CI
Oryzon Announces First Patient in Frida, A Phase Ib Trial with Iadademstat in Relapsed Refractory Flt3-Mutant Acute Myeloid Leukemia Patients	23-03-15	CI
Oryzon Genomics, S.A. Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders	23-03-13	CI
Oryzon Genomics S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-17	CI
Oryzon Genomics S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-17	CI
Oryzon Genomics S.A. announced that it has received €1.800407 million in funding	22-12-19	CI
ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas	22-11-09	CI
Spain's Oryzon Genomics Wins US FDA Nod for Mid-stage Study of Investigational Cancer Drug	22-11-09	MT
Oryzon Genomics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-02	CI
Oryzon Genomics S.A. to Present Preliminary Blinded Aggregate Safety Data from Vafidemstat's Ongoing Phase Iib Portico Trial in Borderline Personality Disorder	22-09-16	CI
Oryzon Genomics S.A. Announces Start of A Preclinical Collaboration with the CMT Research Foundation	22-07-26	CI

Oryzon Genomics SA, is a Spain-based clinical phase biopharmaceutical company, which discovers and develops drugs based on epigenetics for the treatment of oncological and neurological diseases. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The Company also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.

Sector

Biotechnology & Medical Research

Calendar

2024-04-29 - LSX World Congress

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2 EUR

Average target price

6.676 EUR

Spread / Average Target

+233.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ORYZON GENOMICS S.A.	+5.93%	123M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research